Nicholas Ashton - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Nicholas Ashton's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Nicholas Ashton
Verified
Gothenburg
Beats
Autism parenting, Manchester working from home, reviews, toys books, lifestyle, theatreCovers: parenting, bereavement, Salford travel, technology
Crime, Politics, Sport, Business
Content
Associations between fluid biomarkers and PET imaging ([11C]UCB-J) of synaptic pathology in Alzheimer's disease
By Johanna Nilsson, Adam P. Mecca, Nicholas Ashton, Elaheh Salardini| bioRxiv@ AbstractINTRODUCTION: Positron Emission Tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer's disease (AD). We investigate the relationship between SV2A PET and CSF synaptic protein changes of AD patients. METHOD: Twenty-one participants with early AD and 7 cognitively normal (CN) individuals underwent [11C]UCB-J PET.
Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window
By Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas Ashton, Christine Déry| Wiley Online Library Verified 1 BACKGROUND The core pathological hallmarks that define Alzheimer's disease (AD) are plaque-forming aggregates of amyloid beta (Aβ) and neurofibrillary tangles of hyper-phosphorylated tau (p-tau).
Associations between fluid biomarkers and PET imaging ([11C]UCB-J) of synaptic pathology in Alzheimer's disease
By Johanna Nilsson, Adam P. Mecca, Nicholas Ashton, Elaheh Salardini| bioRxiv@ AbstractINTRODUCTION: Positron Emission Tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer's disease (AD). We investigate the relationship between SV2A PET and CSF synaptic protein changes of AD patients. METHOD: Twenty-one participants with early AD and 7 cognitively normal (CN) individuals underwent [11C]UCB-J PET.
Company Info
Gothenburg, Vaestra Goetaland County, Sweden
+46 31 786 00 00